Search results
View the latest Avalo Therapeutics Inc. (AVTX) stock price, news, historical charts, analyst ratings and financial information from WSJ.
Avalo Therapeutics Inc. analyst ratings, historical stock prices, earnings estimates & actuals. AVTX updated stock price target summary.
Sep 13, 2023 · Investors are celebrating the asset sale agreement with heavy trading of AVTX stock. As of this writing, more than 62 million shares have changed hands. That’s already well above its daily ...
Avalo Therapeutics (AVTX) stock price nosedived on Monday after the company published relatively weak financial results. It tumbled by over 23.5% in the pre-market session and reached a low of... Avalo Therapeutics EPS of -$114.00, revenue of $1.92M beats by $0.72M SeekingAlpha.com: All News • about 2 months ago
Find the latest Avalo Therapeutics, Inc. (AVTX) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.
Feb 6, 2023 · Shares of Avalo Therapeutics Inc (AVTX) dropped by 11.53% from $0.198 to $0.175 in the trading on Friday, August 4, 2023. The reason why AVTX down is due to its lower-than-expected quarterly earnings report. Avalo Therapeutics reported a loss of $0.59 per share, surpassing the Zacks Consensus Estimate, which had predicted a loss of $0.90 per share.
May 20, 2024 · Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company’s drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T ...
